FDA Updates Durvalumab NSCLC Label to Include OS Data

July 22, 2019 – The FDA has updated the label for durvalumab for patients with unresectable, stage III non–small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemoradiation to include overall survival (OS) data from the phase III PACIFIC trial. In results of the primary OS analysis, the PD-1 inhibitor demonstrated a 32% reduction in the risk of death compared with placebo, which was a significant and clinically … (leggi tutto)